The proposed changes to the Medicaid best price rule put forward by CMS may give drug manufacturers and payers regulatory flexibility to encourage more use of value-based contracting arrangements for expensive, but promising therapies.
The proposed changes to the Medicaid best price rule put forward by CMS may give drug manufacturers and payers regulatory flexibility to encourage more use of value-based contracting arrangements for expensive, but promising therapies.